|Bid||0.00 x 1200|
|Ask||0.00 x 1000|
|Day's Range||95.98 - 101.75|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb. 24, 2020 - Feb. 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||206.93|
CARLSBAD, Calif., Dec. 07, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription.
GW Pharmaceuticals plc (NASDAQ:GWPH) shareholders might be concerned after seeing the share price drop 26% in the last...
LONDON and CARLSBAD, Calif., Dec. 05, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid.
FDA Says CBD Can Hurt Your Liver Potentially speaking. Potentially, anything can hurt your liver, but that isn’t stopping the Food and Drug Administration from singling out cannabidiol (CBD), the nonpsychoactive cannabinoid generally recognized as safe by most people, but not officially so by the FDA. The compound is now sold in pharmacies including CVS […]The post Market Morning: CBD Warning, Chemocentryx Win, Huge Tory Majority, Amazon Injuries appeared first on Market Exclusive.
CARLSBAD, Calif., Nov. 22, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in.
GW Pharmaceuticals, NetGear, Cisco Systems and NetApp highlighted as Zacks Bull and Bear of the Day
Globus Medical (GMED) is on course to commercially market ExcelsiusGPS platform and launch its spine deformity solution in early fourth quarter.
This study result is expected to be a major stride forward in Hologic's (HOLX) commitment toward strengthening its Diagnostic Solutions business.
Medtronic (MDT) presents favorable results from study on leadless pacemaker, indicating potential for improving cardiac functions in patients having blockages.
GW Pharmaceuticals plc (GWPH) (“GW”, “the Company” or “the Group”), world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England. This represents the first-time any plant-derived cannabis-based medicine has been recommended by NICE for use on the NHS.